Posts by carla
Aspira Women’s Health Announces Publication of Data Demonstrating Performance of its In-Development Blood Test for the Assessment of Malignancy Risk in Patients with an Adnexal Mass
SUMMARY: The addition of miRNA and metadata to Aspira’s existing protein assay shows promising improvements in both sensitivity and specificity for early-stage ovarian cancer in women with an adnexal mass AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development…
Read MoreAspira Women’s Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference
AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women’s Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11,…
Read MoreAspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub
SUMMARY: “Spoke” designation acknowledges Aspira’s position as an innovator in women’s health, and provides new opportunities for funding, thought leadership and networking with other healthcare industry leaders AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease…
Read MoreAspira Women’s Health Partners with Dorsata to Create New Clinical Workflow Tool for Adnexal Masses
SUMMARY: The innovative new tool will be made available for integration into Electronic Medical Records at over 300 clinical sites serving 2,500 clinical users AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today…
Read MoreAspira Women’s Health Reports Second Quarter 2024 Financial Results
SUMMARY Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc.…
Read MoreAspira Women’s Health Announces Poster Presentation at the Menopause Society’s 2024 Annual Meeting
Presentation to highlight data demonstrating OvaWatch’s performance in assessing ovarian cancer risk in pre- and post-menopausal women August 01, 2024 08:00 ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a…
Read MoreAspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12
July 31, 2024 16:05 ET AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30,…
Read MoreAspira Women’s Health Appoints Mr. John Ragard to its Board of Directors
SUMMARY: Mr. Ragard further strengthens the Board bringing more than 46 years of significant public equity investment and Wall Street experience DOWNLOAD THIS POST AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today…
Read More